Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Screening Study for Participants With Malignant Tumors
Screening Study for Participants With Malignant Tumors

NCT05419375

CompletedPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Solid Tumors

Interventions: Screening platform

Countries: United States, Australia, Brazil, Canada, Chile, Colombia, Costa Rica, France

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
General Inclusion Criteria:

* Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
* Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial

Inclusion Criteria for Participants with Stage III NSCLC

* Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Inclusion Criteria for Participants with Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC Requiring Adjuvant Treatment

* Stage II, IIIA, or select IIIB (T3N2 only) NSCLC based on the 8th edition of the AJCC and UICC cancer staging system (Amin et al. 2017)
* Considered eligible for curative intent surgery (complete resection with all surgical margins testing negative for tumor)
* Screening within Study BX43361, using a pretreatment biopsy, is encouraged to be performed as early in the participant treatment pathway as possible to ensure the participant is potentially eligible for all cohorts, and should meet guidelines as defined by the protocol
* Representative FFPE tumor specimen obtained prior to the start of any treatment
* ECOG Performance Status of 0 or 1

General Exclusion Criteria:

* History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
* Any condition that may affect the interpretation of study results
* Significant liver or cardiovascular disease
* Prior allogenic stem-cell or solid-organ transplantation
Locations (79)
  • Knoxville, Tennessee, United States
  • Austin, Texas, United States
  • Tyler, Texas, United States
  • Blacksburg, Virginia, United States
  • Vancouver, Washington, United States
  • Nedlands, Western Australia, Australia
  • Uberlândia, Minas Gerais, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • Blumenau, Santa Catarina, Brazil
  • São Paulo, São Paulo, Brazil
  • Rio de Janeiro, Brazil
  • Toronto, Ontario, Canada
  • Santiago, Chile
  • Santiago, Chile
  • Barranquilla, Colombia
  • Bogotá, Colombia
  • Medellín, Colombia
  • San José, Costa Rica
  • San José, Costa Rica
  • Lyon, France
  • Toulon, France
  • München, Germany
  • München-Gauting, Germany
  • Hong Kong, Hong Kong
  • Gurgaon, Haryana, India
  • Haifa, Israel
  • Rome, Lazio, Italy
  • Aichi, Japan
  • Hyōgo, Japan
  • + 49 more on CT.gov